REGN7999

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

HealthyNon-Transfusion Dependent Beta-Thalassemia (NTDT)

Phase 1

A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants

CompletedNCT05481333

Regeneron PharmaceuticalsHealthy

Start: 2022-10-24End: 2023-08-29Updated: 2024-07-24

Phase 2

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

Active, not recruitingNCT06421636

Regeneron PharmaceuticalsNon-Transfusion Dependent Beta-Thalassemia (NTDT)

Start: 2024-09-30End: 2026-12-03Updated: 2026-07-01

Related Papers

A TMPRSS6-inhibiting mAb improves disease in a β-thalassemia mouse model and reduces iron in healthy humans

JCI Insight2025-06-221 citations

Single Ascending Doses of REGN7999, a Monoclonal Antibody Inhibitor of TMPRSS6, Increase Serum Hepcidin and Cause Deep, Sustained Reductions in Serum Iron in Healthy Human Volunteers

Blood2023-11-021 citations